Viloxazine hydrochloride - Generic Drug Details

What are the generic sources for viloxazine hydrochloride and what is the scope of freedom to operate?

Viloxazine hydrochloride is the generic ingredient in one branded drug marketed by Supernus Pharms and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Viloxazine hydrochloride has twenty-two patent family members in seven countries.

One supplier is listed for this compound.

Summary for viloxazine hydrochloride

International Patents:	22
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	89
Clinical Trials:	13
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for viloxazine hydrochloride
What excipients (inactive ingredients) are in viloxazine hydrochloride?	viloxazine hydrochloride excipients list
DailyMed Link:	viloxazine hydrochloride at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for viloxazine hydrochloride

Dosage:

CAPSULE, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for viloxazine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Supernus Pharmaceuticals, Inc.	PHASE4
Apnimed	Phase 2
Supernus Pharmaceuticals, Inc.	Phase 4

See all viloxazine hydrochloride clinical trials

Pharmacology for viloxazine hydrochloride

Drug Class	Norepinephrine Reuptake Inhibitor
Mechanism of Action	Cytochrome P450 1A2 Inhibitors Cytochrome P450 2B6 Inhibitors Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A4 Inhibitors Norepinephrine Uptake Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for viloxazine hydrochloride

N06AX	Other antidepressants
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for VILOXAZINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
QELBREE	Extended-release Capsules	viloxazine hydrochloride	200 mg	211964	8	2025-04-02

US Patents and Regulatory Information for viloxazine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-001	Apr 2, 2021		RX	Yes	No
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-003	Apr 2, 2021		RX	Yes	Yes
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-003	Apr 2, 2021		RX	Yes	Yes

International Patents for viloxazine hydrochloride

Country	Patent Number	Title	Estimated Expiration
Spain	2950875
World Intellectual Property Organization (WIPO)	2010028207
Japan	6510093

Market Dynamics and Financial Trajectory for Viloxazine Hydrochloride

Last updated: February 13, 2026

Overview Viloxazine hydrochloride (Viloze) is a non-amphetamine selective serotonin reuptake inhibitor (SSRI) originally developed as an antidepressant in the 1970s. It has re-emerged within the ADHD treatment landscape under regulatory consideration and commercial development. Its unique pharmacology positions it distinctively within the central nervous system (CNS) therapeutic market.

Regulatory Status and Approval Timeline

• Development history: Evergreening of viloxazine for ADHD occurred after its initial antidepressant approval in the 1970s in Europe and Japan.
• FDA designation: The U.S. Food and Drug Administration (FDA) granted viloxazine a priority review in 2021 for ADHD in pediatric and adult patients.
• Approval: The FDA approved viloxazine (brand: Qelbree) for ADHD treatment in children aged 6-17 in April 2021 and for adults in October 2022.

Market Environment

• Size of ADHD market: Estimated USD 20 billion global market in 2022. The U.S. accounts for approximately 60% of sales, driven by high diagnosis rates, especially in children and adolescents.
• Competitive landscape: Dominated by stimulant medications (e.g., methylphenidate, amphetamines) accounting for roughly 70% of prescriptions, with non-stimulants such as atomoxetine and guanfacine holding the remainder.
• Unmet needs: Approximately 30-40% of patients do not respond well to existing therapies or experience adverse effects. Viloxazine aims to address this segment, especially among patients preferring non-stimulant options.

Market Dynamics Factors

• Physician and patient acceptance: The favorable side effect profile reported in clinical trials (less risk of dependence, lower cardiovascular impact) encourages adoption.
• Pricing policies: In the U.S., viloxazine is marketed at approximately USD 850-950 per month for pediatric formulations, comparable to non-stimulant competitors.
• Market penetration: Initial uptake has been steady; recent data suggest around 10% of newly diagnosed ADHD patients in the U.S. received viloxazine within the first year post-launch.
• Reimbursement landscape: Insurance coverage is critical; initial coverage is broad, but formulary positioning affects market share escalation.

Financial Trajectory and Revenue Potential

• Sales projections: Analysts project that viloxazine could reach USD 500 million annually within five years in the U.S., assuming a 15-20% market share among non-stimulant ADHD medications.
• Growth factors: Increased diagnosis rates, expanding adult indications, and higher dosing approvals aim to drive revenue growth.
• Global opportunities: Currently limited outside the U.S. due to regulatory timelines. European and Asian approvals are anticipated over the next 18-24 months.

Risks and Challenges

• Competitive pressure: Stimulant market dominance persists; non-stimulant share remains limited.
• Regulatory uncertainties: Future indications or labeling adjustments could impact sales.
• Generic competition: Entry of cheaper generic options for existing non-stimulants could pressure margins.

Historical Financial Data & Trends

• Initial sales: Mana Pharmaceuticals reported USD 10 million in Q2 2022 post-launch.
• Growth rates: Projected compound annual growth rate (CAGR) of approximately 25% over five years.
• Cost considerations: High R&D and marketing expenses expected to delay profitability until year three or four. Early investment in physician education program anticipated to improve uptake.

Key Takeaways

• Viloxazine hydrochloride has gained FDA approval as a non-stimulant ADHD therapeutic with a favorable safety profile.
• The U.S. ADHD market exceeds USD 20 billion annually; viloxazine is poised for accelerated growth due to unmet needs addressed.
• Sales are expected to reach USD 500 million within five years if market penetration remains consistent.
• Competitive landscape favors stimulants; viloxazine's success depends on physician and patient acceptance, reimbursement, and geographic expansion.
• Risks include market share erosion by generic competitors and regulatory hurdles for broader indications.

FAQs

1. Is viloxazine hydrochloride approved outside the United States? No. As of Q1 2023, it remains under regulatory review or awaiting approval in Europe and Asia. The timeline for international approval extends 12-24 months.

2. What differentiates viloxazine from existing ADHD medications? It is a selective serotonin reuptake inhibitor with a lower dependence potential and a different side effect profile compared to stimulants. It also targets a segment of patients who do not tolerate stimulants well.

3. What is the expected market share for viloxazine in ADHD? Forecasts are optimistic with a potential 15-20% share among non-stimulant medications within five years, translating to potentially USD 500 million in annual revenue in the U.S.

4. Are there patent protections or exclusivity rights for viloxazine? Yes. The initial formulation and specific delivery mechanisms offer exclusivity until approximately 2035, with additional patents potentially extending market protection.

5. What are potential barriers to commercial success? Competition from established stimulant therapies, insurance coverage constraints, and regulatory constraints for international expansion.

References

1. IQVIA. (2022). Global ADHD Market Data.
2. FDA. (2021-2022). Approval documents for viloxazine (Qelbree).
3. MarketWatch. (2023). ADHD drug market analysis.
4. Pfizer Annual Report. (2022). ADHD treatment portfolio overview.
5. Industry analyst estimates. (2023). Revenue forecast models for viloxazine.

---